Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides

A method of improving the health of an individual requiring treatment for a medical condition, for reducing or eliminating a medical condition in an individual requiring treatment for said condition, for reverting a mutated nucleotide in a target nucleic acid to the wild-type nucleotide, for modifying a non-mutated nucleotide of a mutated codon in a target nucleic acid to produce a wild-type codon, for converting a stop codon in a target nucleic acid to a read through non-wild type codon, for modifying a mutated codon in a target nucleic acid to produce a non-wild type codon that results in a non-disease causing amino acid, for modifying a nucleic acid encoding a protein to modulate said protein's activity, for modifying a nucleic acid encoding a mutant protein to suppress its disease causing affects comprising:

• administering to a cell or an individual a single-stranded chemically modified oligonucleotide without additional proteins or nucleic acids to assist in editing said genomic sequence, wherein said modifications are phosphorothioate backbone modifications, wherein said oligonucleotide is complementary to a target sequence in said genomic sequence, wherein said modifications of said oligonucleotide increase the efficiency of editing by increasing the nuclease stability as compared to unmodified oligonucleotides or oligonucleotides having three phosphorothioates on each termini, optionally wherein at least one of said mutated nucleotide is reverted to said wild-type nucleotide, said mutated codon is modified to said wild-type codon, said stop codon is modified to said read through non-wild type codon, said mutated codon is modified to a non-wild type codon that results in a non-disease causing amino acid, said protein's activity is modulated, said mutant proteins disease causing affects are decreased, suppressed or eliminated.

An editing oligonucleotide for site-specific modification of a target nucleic acid comprising the structure:

• wherein:
• each oligonucleotide is substantially complementary to said target nucleic acid and is about 10 to about 50 nucleotides;
• X is H, OH, halogen, R1, SR1 or OR1;
• halogen is Cl, F, Br or I;
• and
• R1 is —CH3, —CH2CH3 or —CH2OCH3;
• wherein:
• each oligonucleotide is substantially complementary to said target nucleic acid and is about 10 to about 50 nucleotides;
• X is H, OH, halogen, R1, SR1 or OR1;
• halogen is Cl, F, Br or I;
• and
• R1 is —CH3, —CH2CH3 or —CH2OCH3;
• wherein:
• each oligonucleotide is substantially complementary to said target nucleic acid and is about 10 to about 50 nucleotides;
• X is H, OH, halogen, R1, SR1 or OR1;
• halogen is Cl, F, Br or I;
• and
• R1 is —CH3, —CH2CH3 or —CH2OCH3;
• wherein:
• each oligonucleotide is substantially complementary to said target nucleic acid and is about 10 to about 50 nucleotides;
• X is H, OH, halogen, R1, SR1 or OR1;
• halogen is Cl, F, Br or I;
• and
• R1 is —CH3, —CH2CH3 or —CH2OCH3;
• wherein each oligonucleotide is substantially complementary to said target nucleic acid and is about 10 to about 50 nucleotides:
• wherein each oligonucleotide is substantially complementary to said target nucleic acid and is about 10 to about 50 nucleotides:
• wherein each oligonucleotide is substantially complementary to said target nucleic acid and is about 10 to about 50 nucleotides.